Novartis drug combo cuts neuroendocrine tumour size

ZURICH, June 24 (Reuters) - A combination of two drugs from Novartis AG (NOVN.VX) cut the size of pancreatic neuroendocrine tumours (NET) in more than 80 percent of patients in a mid-stage study, the Swiss group said on Wednesday. Patients who received once daily pill Afinitor in combination with Sandostatin LAR, an approved treatment for symptom control in certain types of NET, had no progression in their disease for a median of 16.7 months, according to results from the so-called RADIANT-1 study. (Reporting by Sam Cage)